Secondary prevention of atherothrombotic or cryptogenic stroke.
Stanford Stroke Center, Stanford University, Palo Alto, CA.
Waimei A
WA
Tai
Gregory W
GW
Albers
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D000069059:Atorvastatin; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors; D055502:Secondary Prevention / Q000379:methods*; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D006538:Heptanoic Acids; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin